These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. Mor A; Bingham CO; Barisoni L; Lydon E; Belmont HM J Rheumatol; 2005 Apr; 32(4):740-3. PubMed ID: 15801034 [TBL] [Abstract][Full Text] [Related]
24. A case of tuberculous arthritis following the use of etanercept. Choi SW; Ahn JJ; Hwang YT; Koh SH; Cho SD Korean J Intern Med; 2009 Dec; 24(4):397-401. PubMed ID: 19949742 [TBL] [Abstract][Full Text] [Related]
28. A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent? Santiago T; Santiago MG; Rovisco J; Duarte C; Malcata A; da Silva JA Clin Rheumatol; 2013 Dec; 32(12):1819-22. PubMed ID: 23955767 [TBL] [Abstract][Full Text] [Related]
29. Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis. Cho SK; Oh IH; Park CK; Bae SC; Sung YK Rheumatol Int; 2012 Apr; 32(4):1055-7. PubMed ID: 20062996 [TBL] [Abstract][Full Text] [Related]
30. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960 [TBL] [Abstract][Full Text] [Related]
31. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Haraoui B; Keystone E Curr Opin Rheumatol; 2006 Jan; 18(1):96-100. PubMed ID: 16344625 [TBL] [Abstract][Full Text] [Related]
32. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328 [TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114 [TBL] [Abstract][Full Text] [Related]
34. Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature. Shovman O; Tamar S; Amital H; Watad A; Shoenfeld Y Clin Rheumatol; 2018 Feb; 37(2):563-568. PubMed ID: 29063464 [TBL] [Abstract][Full Text] [Related]